BridgeBio Pharma, Inc. Warrants Not Settleable in Cash, Fair Value Disclosure
BridgeBio Pharma, Inc. (BBIO) had Warrants Not Settleable in Cash, Fair Value Disclosure of $1.60 million as of 2023-12-31, per its 10-K filed 2025-02-20.
Financial Statements › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
us-gaap:WarrantsNotSettleableInCashFairValueDisclosure · last filed 2025-02-20
- 2023-12-31: Warrants Not Settleable in Cash, Fair Value Disclosure $1.60M.
- 2023-09-30: Warrants Not Settleable in Cash, Fair Value Disclosure $500.00K.
- 2023-06-30: Warrants Not Settleable in Cash, Fair Value Disclosure $800.00K.
- 2023-03-31: Warrants Not Settleable in Cash, Fair Value Disclosure $700.00K.
| Period end | Warrants Not Settleable in Cash, Fair Value Disclosure |
|---|---|
| 2023-12-31 | $1.60M 10-K · filed 2025-02-20 |
| 2023-09-30 | $500.00K 10-Q · filed 2023-11-02 |
| 2023-06-30 | $800.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $700.00K 10-Q · filed 2023-05-04 |
| 2022-12-31 | $600.00K 10-K · filed 2024-02-22 |
| 2022-09-30 | $700.00K 10-Q · filed 2022-11-03 |
| 2022-06-30 | $800.00K 10-Q · filed 2022-08-04 |
| 2022-03-31 | $1.30M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $2.10M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |